Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis

European Psychiatry

Volumn 28, Issue 6, 2013, Pages 362-371

  Gorwood, P ^a,b   Bayle, F ^a,b   Vaiva, G ^c   Courtet, P ^d   Corruble, E ^e   Llorca, P M ^f  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e Universite Paris Sud   (France)

^f UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Early response; Major depressive disorder; Marker; Outcome; Treatment response

Indexed keywords

AGOMELATINE; AMITRIPTYLINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; MOCLOBEMIDE; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD; MULTICENTER STUDY; OUTPATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; REMISSION; SLEEP; TREATMENT RESPONSE;

EARLY RESPONSE; MAJOR DEPRESSIVE DISORDER; MARKER; OUTCOME; TREATMENT RESPONSE;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84880753080     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2012.11.004     Document Type: Article

References (56)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington DC. Fourth ed., text revision.
2. American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder 2010, APA, Arlington, USA. Third edition.
3. Anderson I.M., Ferrier I.N., Baldwin R.C., et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008, 22:343-396.
4. Baldwin D., Stein D., Dolberg O., Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol Clin Exp 2009, 24:269-275.
5. Bares M., Novak T., Kopecek M., Stopkova P., Kozeny J., Höschl C. The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data. Eur Psychiatry 2012, 27(7):522-527.
6. Bauer M., Whybrow P.C., Angst J., Versiani M., Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002, 3:5-43.
7. Bech P., Cialdella P., Haugh M.C., et al. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000, 176:421-428.
8. Bech P. Social functioning: should it become an endpoint in trials of antidepressants?. CNS Drugs 2005, 19(4):313-324.
9. Bonett D., Price R. Statistical inference for generalized Yule coefficients in 2×2 contingency tables. Sociol Methods Res 2007, 35:429-446.
10. Casper R.C., Katz M.M., Bowden C.L., Davis J.M., Koslow S.H., Hanin I. The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine. J Affect Disord 1994, 31:151-164.
11. Coryell W., Coppen A., Zeigler V.E., Biggs J.T. Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparison of 2 patient samples. Psychol Med 1982, 12:135-139.
12. Gelenberg A.J., Chesen C.L. How fast are antidepressants?. J Clin Psychiatry 2000, 61:712-721.
13. Gorwood P., Corruble E., Falissard B., Goodwin G.M. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry 2008, 165:731-739.
14. Gorwood P. Restoring circadian rhythms: a new way to successfully manage depression. J Psychopharmacol 2010, 24:15-19.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
16. Henkel V., Seemuller F., Obermeier M., et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 2009, 115:439-449.
17. Hickie I.B., Rogers N.L. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011, 378(9791):621-631.
18. Hirschfeld R.M., Dunner D.L., Keitner G., Klein D.N., Koran L.M., Kornstein S.G., et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 2002, 51(2):123-133.
19. Howard K.I., Lueger R.J., Maling M.S., Martinovich Z. A phase model of psychotherapy outcome: causal mediation of change. J Consult Clin Psychol 1993, 61(4):678-685.
20. Katz M.M., Koslow S.H., Maas J.W., et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987, 17:297-309.
21. Kennedy S.H., Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006, 16:93-100.
22. Kessler R.C., Aguilar-Gaxiola S., Alonso J., et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psychiatr Soc 2009, 18(1):23-33.
23. Kim J.M., Kim S.Y., Stewart R., et al. Improvement within 2weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study. J Affect Disord 2011, 129:183-190.
24. Lam R.W., Kennedy S.H., Grigoriadis S., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009, 117:S26-S43.
25. Leuchter A.F., Uijtdehaage S.H., Cook I.A., O'Hara R., Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res Neuroimaging 1999, 90(2):125-140.
26. Li J., Kuk A.Y., Rush A.J. A practical approach to the early identification of antidepressant medication non-responders. Psychol Med 2012, 42(2):309-316.
27. Lôo H., Hale A., D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002, 17:239-247.
28. Marangell L.B. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001, 62:12-17.
29. National Institute for Health Clinical Excellence CG90 Depression in adults: NICE guidance 2009, NICE, London.
30. National Institute of Mental Health CGI, Clinical Global Impression. ECDEU Assessment Manual of Psychopharmacology Review 1976, 217-222. NIMH, Rockville, USA. W. Guy (Ed.).
31. Nierenberg A.A., McLean N.E., Alpert J.E., Worthington J.J., Rosenbaum J.F., Fava M. Early non-response to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995, 152:1500-1503.
32. Nierenberg A., Greist J., Mallinckrodt c, Prakash A., Sambunaris A., Tollefson G., et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007, 23:401-416.
33. Olesen J., Gustavsson A., Svensson M., Wittchen H.U., Jönsson B., CDBE2010 study group, et al. The economic cost of brain disorders in Europe. Eur J Neurol 2012, 19(1):155-162.
34. Olié J.P., Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007, 10:661-673.
35. Papakostas G.I., Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009, 19:34-40.
36. Parrott A.C., Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations: a review. Psychopharmacology (Berl) 1980, 71:173-179.
37. Posternak M.A., Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 2005, 66(2):148-158.
38. Quitkin F.M., Rabkin J.D., Markowitz J.M., Stewart J.W., McGrath P.J., Harrison W. Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry 1987, 44:259-264.
39. Rosenberg M.S., Adams D.C., Gurevitch J. Meta Win. Statistical software for meta-analysis. Version 2 2000, Massachusetts: Sinauer Associates, Sunderland.
40. Rothwell P.M. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 2005, 365:82-93.
41. Rush A.J., Trivedi M.H., Ibrahim H.M., et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54:573-583.
42. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354:1231-1242.
43. Sheehan D.V., Harnett-Sheehan K., Raj B.A. The measurement of disability. Int Clin Psychopharmacol 1996, 11:89-95.
44. Srinivasan V., De Berardis D., Shillcutt S.D., Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs 2012, 21(10):1503-1522.
45. Stassen H., Angst J., Delini-Stula A. Onset of improvement under fluoxetine and moclobemide. Eur Psychiatry 1998, 13:128-133.
46. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000, 283(15):2008e12.
47. Swanson K.A., Bastani R., Rubenstein L.V., Meredith L.S., Ford D.E. Effect of mental health care and shared decision making on patient satisfaction in a community sample of patients with depression. Med Care Res Rev 2007, 64:416-430.
48. Szegedi A., Jansen W.T., van Willigenburg A.P., van der Meulen E., Stassen H.H., Thase M.E. Early improvement in the first 2weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009, 70:344-353.
49. Tadić A., Helmreich I., Mergl R., et al. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord 2010, 120:86-93.
50. Tadić A., Wagner S., Gorbulev S., Dahmen N., Hiemke C., Braus D., et al. Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with major depressive disorder. BMC Psychiatry 2011, 11:16.
51. Thornicroft G., Sartorius N. The course and outcome of depression in different cultures: 10-year follow-up of the WHO Collaborative Study on the Assessment of Depressive Disorders. Psychol Med 1993, 23:1023-1032.
52. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
53. van Calker D., Zobel I., Dykierek P., Deimel P., Kech S., Lieb K., et al. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. J Affect Disord 2009, 114:243-253.
54. Wade A., Friis Andersen H. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 2006, 22:2101-2110.
55. Walsh B.T., Seidman S.N., Sysko R., Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002, 287:1840-1847.
56. Winokur G. What to do? Or what do we owe our residents?. Biol Psychiatry 1980, 15:599-611.